29.09.2015 • NewsDede WillamsSanofiEli Lilly

Sanofi and Lilly Settle Lantus Patent Row

France’s Sanofi and US drugmaker Eli Lilly have resolved their patent dispute over insulin drugs.

The settlement announced this week ends a US lawsuit brought by the French producer of Lantus SoloSTAR (insulin glargine) in response to its US rival’s pursuit of regulatory approval for a competitive product. The two companies also agreed to discontinue similar disputes worldwide.

As part of the agreement, Lilly will pay royalties to Sanofi in exchange for a license to certain Sanofi patents and will not sell its insulin glargine product on the US market before Dec.15, 2016. The agreement does not extend to Lantus (vial), Toujeo or combination products.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.